Previous close | 2.3100 |
Open | 2.3100 |
Bid | 2.5600 x 200 |
Ask | 2.6200 x 100 |
Day's range | 2.3097 - 2.6300 |
52-week range | 1.0500 - 2.6300 |
Volume | |
Avg. volume | 224,959 |
Market cap | 161.382M |
Beta (5Y monthly) | 1.10 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.5100 |
Earnings date | 06 Aug 2024 - 12 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 7.83 |
Data demonstrated in vitro and in vivo ITK inhibition with soquelitinib induced switching of proinflammatory Th17 cells into anti-inflammatory Treg cells Publication confirms and extends understanding of ITK inhibition mechanism of action and its potential in inflammatory autoimmune and allergic diseases Data published by leading researchers from Cornell University in peer-reviewed journal Science Signaling BURLINGAME, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvu
Key Insights Significant control over Corvus Pharmaceuticals by retail investors implies that the general public has...
BURLINGAME, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president and chief executive officer, and Jeffrey Arcara, chief business officer, will conduct one-on-one meetings with investors and present a corporate overview at the Jefferies Global Health Conference, which is being held in New York from June 5-7, 2024. The Company’s presentation will be on Wednesday, Jun